Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
Journal: Lancet (London, England)
Published: February 02, 2026
Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein disease.
Journal: NPJ Parkinson's disease
Published: January 17, 2026
Synergistic effects of APOE ε4 and Alzheimer's pathology on the neural correlates of episodic remembering in cognitively unimpaired older adults.
Journal: bioRxiv : the preprint server for biology
Published: July 16, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial.
Journal: medRxiv : the preprint server for health sciences
Published: February 20, 2025
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
Journal: Journal of Alzheimer's disease : JAD
Published: December 17, 2024
Biologically defined neuronal synuclein disease as a tool to advance drug development.
Journal: NPJ Parkinson's disease
Published: October 31, 2024
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
Journal: The Lancet. Neurology
Published: September 05, 2024
Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction.
Journal: NPJ Parkinson's disease
Published: August 26, 2024
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Journal: Journal of Alzheimer's disease : JAD
Published: August 23, 2024
Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: August 06, 2024
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
Journal: The journal of prevention of Alzheimer's disease
Published: May 06, 2024
Last Updated: 09/26/2026